Trial · NCT04677803
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemophilia A | Baseline through 4 weeks after dosing | increase in FVIII activity |
| Primary | VWD Type 1 | Baseline through 4 weeks after dosing | increase in FVIII activity |
| Primary | VWD Type 2b | Baseline through 4 weeks after dosing | increase in platelet count and/or FVIII activity |
| Secondary | Pharmacokinetic (PK) Measured concentration of BT200 (and derived PK parameters) | Baseline through 4 weeks after dosing | Measured concentration of BT200 |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | PFA-100 |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | Multiplate electrode platelet aggregometer (ristocetin induced) |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | VWF antigen |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | VWF:ristocetin co-factor assay |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | VWF activity |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | VWF collagen bindign assay |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | ELISA for unbound VWF-A1 domain |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | VWF propeptide |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | Fibrin D-Dimer |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | Prothrombin fragement (F1.2) |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | Rotational thrombelastometry |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | Clot strength assay |
| Secondary | Pharmacodynamics | Baseline through 4 weeks after dosing | Calibrated Thrombogram assay |
| Other | Overall safety and tolerability of BT200 | Baseline through 4 weeks after dosing | Serious, drug-related adverse events (AEs) |
| Other | Overall safety and tolerability of BT200 | Baseline through 4 weeks after dosing | Patterns of serious or non-serious, drug-related AEs and/or clinically relevant laboratory abnormalities, vital signs, or physical findings suggestive of one or more specific target organs for toxicity of BT200 |
| Other | Overall safety and tolerability of BT200 | Baseline through 4 weeks after dosing | Clinically evident bleeding assessed using the International International Society on Thrombosis and Haemostasis (ISTH) Bleeding Score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04677803/registered